Dyne Therapeutics

DYN

Market cap $2.83B

It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind.

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. Accelerated Approval in Q2 2026 -

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list.

Dyne Therapeutics' stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought out for a big premium.

Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects key catalysts: DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late 2026. The pipeline includes zeleciment rostudirsen for DMD exon 51 skipping patients, with registrational cohort data expected in late 2025 and a potential BLA in early 2026.

- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.

WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company.

- Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 -

Dyne Therapeutics, Inc. (NASDAQ:DYN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants John Cox - CEO, President & Director Erick Lucera - CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.